Research peptide vendors are dropping recognizable compound names — even informal shorthands like "GLP-2" — in favor of invented house names ("pp-2T," "X-2," "Perfect T"). The real compound identity is now buried in the Certificate of Analysis, if it appears at all. This shift is a deliberate response to FDA enforcement escalation, payment processor keyword blacklisting, and pharmaceutical company litigation — all of which are triggered more easily by explicit compound names than by opaque house labels. The practical consequence: the COA is no longer just a quality-assurance document. It's now the only reliable way to know what you're buying.
The naming evolution
A few years ago, vendor listings were reasonably transparent. If you searched for tirzepatide, you'd find it labeled as "Tirzepatide 10mg." By 2024, many vendors had moved to the informal shorthand — "GLP-2" or "GLP-2 T" — which wasn't a recognized medical term, but at least gestured toward the compound. By 2025 and into 2026, a significant number of vendors have dropped even that much. The listing says "pp-2T" or "Perfect T" or simply a brand name with a letter appended. The compound name doesn't appear anywhere in the listing. It's in the COA — if the COA is in-house, if it exists at all.
| Era | Listing Name | How to Verify |
|---|---|---|
| 2023–2024 | Tirzepatide 10mg | COA confirms |
| 2024 | "GLP-2" or "GLP-2 T" | COA confirms |
| 2025–2026 | "pp-2T," "X-2," "[brand]-T" | COA only — listing gives no signal |
Why it's happening
Multiple pressure vectors converged on the research peptide market in 2025, and each one hits harder when compound names are visible on a product listing.
FDA enforcement escalated from letters to raids. In December 2024, the FDA issued warning letters to at least four peptide vendors — Xcel Peptides, SwissChems, Summit Research, and Prime Peptides — specifically for listing semaglutide, tirzepatide, and retatrutide by name while marketing them for human use. The agency also began using automated tools to scrape vendor websites for compound names. By June 2025, enforcement moved from warning letters to physical warehouse raids. Amino Asylum was hit in June 2025, forcing it offline overnight. The pattern: visible compound names on the site create targeting exposure. Obfuscated names reduce it.
Payment processors are blocking by keyword. Stripe, PayPal, and Square now routinely freeze accounts tied to peptide sales — especially anything associated with GLP-1 compounds. The screening is largely automated and keyword-based. A listing that says "Tirzepatide 10mg" will trigger account review far faster than one that says "pp-2T." Vendors who moved to house names were buying time with their payment processors.
Pharmaceutical companies are suing. Eli Lilly filed federal lawsuits against telehealth companies distributing tirzepatide in April 2025. Novo Nordisk followed with suits against 14 semaglutide distributors in August 2025. Using a compound's actual name — or widely recognized shorthand — creates a paper trail for trademark and IP claims. A product called "pp-2T" is harder to name in a trademark infringement filing than one explicitly labeled "Tirzepatide (Mounjaro)."
The compounding loophole closed. The FDA's drug shortage designation for semaglutide and tirzepatide ended in 2025. Once it did, the "research use only" framing became the primary remaining legal argument for vendors still selling these compounds. Prominently naming the compound in a listing directly undercuts that argument. House names provide a thin layer of deniability.
Is the COA-burial strategy deliberate?
Almost certainly yes, for most vendors who've adopted it. The structure is intentional: the product listing carries an ambiguous house name with no compound reference, while the COA identifies the actual compound along with purity data. Automated screening — FDA scraping, payment processor keyword matching, pharma company crawlers — doesn't catch the listing. Quality-conscious buyers can still verify via the COA.
This is a rational response to an adversarial environment. The COA exists as a quality-assurance document, which gives vendors legitimate cover for including compound identification there. The listing itself stays clean.
What this means for verification
The COA was already the right verification mechanism. The difference now is that it's the only one. In 2023, a listing that said "GLP-2" gave you at least a strong informal signal about the compound. A listing today that says "pp-2T" gives you almost nothing. Everything rides on the COA.
What this means practically: if a vendor's COA is in-house only, missing, or vague about compound identity, there is no fallback. A third-party lab COA that names the compound and confirms purity is more essential now than it was in prior years. A COA from a recognized lab like Janoshik that you can verify against their public database is the gold standard. An in-house PDF with no verifiable test number is not sufficient — it never was, but it was less dangerous when the listing itself gave you compound confirmation.
The absence of a verifiable COA has always been a red flag. In the current naming environment, it's a dealbreaker.